This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Amgen, TakeTwo Interactive, Chegg, Pfizer and BP
by Zacks Equity Research
Amgen, TakeTwo Interactive, Chegg, Pfizer and BP are included in this blog.
Best Growth Stocks to Buy for February 8th
by Zacks Equity Research
CROX, PFE, and CLS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 8, 2022
Markets Await More Earnings Data
by Zacks Equity Research
Markets Await More Earnings Data
Pfizer (PFE) Q4 Earnings Top, 2022 Sales View Grim, Stock Down
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q4 earnings but misses the same for sales. The sales guidance for 2022 falls short of investor expectations. Stock declines.
NVIDIA/ARM Deal Off, Peloton CEO Steps Down
by Mark Vickery
Tech giant NVIDIA's (NVDA) planned acquisition of Softbank entity Arm Software is no more.
Amgen's (AMGN) Q4 Earnings Top Estimates, Product Sales Fall
by Zacks Equity Research
Amgen (AMGN) beats Q4 estimates for earnings but misses the same for sales. Higher Other Revenue for manufacturing Eli Lilly's COVID-19 antibody boost sales growth.
Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DIV
Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for USMC
Mixed Earnings Results for Amgen, TakeTwo; Chegg Jumps on Beat
by Mark Vickery
After Monday's close, more companies reported earnings results, including Amgen, TakeTwo Interactive and Chegg.
The Markets' Tone: Cautiously Optimistic
by Daniel Laboe
As more market solidifying data hits the wire, the more the uncertain-fueled January correction unwinds
Best Growth Stocks to Buy for February 7th
by Zacks Equity Research
AAPL, TOL, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 7, 2022
Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.
The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer
by Zacks Equity Research
AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.
How Will Pfizer's (PFE) Key Drugs Perform in Q4 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.
Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH
by Sundeep Ganoria
Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.
Pfizer as the Bull of the Day and Mesa Air Group have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Pfizer as the Bull of the Day and Mesa Air Group have been highlighted as Zacks Bull and Bear of the Day.
Bull of the Day: Pfizer Inc. (PFE)
by Bryan Hayes
With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.
Glaxo (GSK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven fourth-quarter sales. The performance of vaccines during Q4 remains to be seen.
Bristol-Myers (BMY) Q4 Earnings Meet Estimates, Sales Beat
by Zacks Equity Research
Bristol-Myers (BMY) earnings match estimates in the fourth quarter of 2021, while sales beat the same on the back of Eliquis and Opdivo.
Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program
by Kinjel Shah
AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.
Sanofi (SNY) Q4 Earnings Beat, Vaccines Hurt Sales Growth
by Zacks Equity Research
Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Is a Surprise Coming for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Best Growth Stocks to Buy for February 4th
by Zacks Equity Research
CROX, PFE, and AAPL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 4, 2022
The Zacks Analyst Blog Highlights: Hasbro Inc., Pfizer Inc., Twilio Inc., CDW Corp. and Annaly Capital Management Inc
by Zacks Equity Research
Hasbro Inc., Pfizer Inc., Twilio Inc., CDW Corp. and Annaly Capital Management Inc are highlighted in this Analyst Blog Article.